The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO Italy 2022 | Exciting advances in DLBCL: molecular characterization of subtypes & novel immunotherapeutic agents
Gerardo Musuraca, MD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy, highlights exciting advances in diffuse large B-cell lymphoma (DLBCL), including the importance of molecular characterization of various subtypes of DLBCL, and the promise of novel immunotherapies, including CAR-T therapy and bispecific antibodies. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
